Gilead Sciences, Inc. (NASDAQ:GILD) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2023 1:30 PM ET Company Participants Dan O’Day - Chairman and CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I’m Chris Schott at JPMorgan, and it’s my pleasure to be introducing Gilead today. From the Company, we’re going to have a presentation fr ...

Justin Sullivan By Valuentum Analysts Gilead Sciences (NASDAQ:GILD) used to be a stock market darling. The firm's drug Sovaldi and its successor Harvoni, a once-daily oral treatment of hepatitis C [HCV] infection, were at one time its key product drivers and accounted for a large percentage of its product sales, but high cure rates and an increasingly crowded HCV market have materially cut its revenue from those products. Gilead is now adapting nicely to new opportunities, and we think it offers investors a ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R ...

Gilead Sciences, Inc. (NASDAQ:GILD) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 9:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Joseph Catanzaro - Piper Sandler Joseph Catanzaro Perfect. Great. Well, appreciate everybody joining us here on the second day of Piper Sandler's Annual Healthcare Conference. I am Joe Catanzaro, one of Piper's biotech analysts. My real pleasure to kick off this session here with Gilead. Joining us is the ...

Gilead Sciences, Inc. (NASDAQ:GILD) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Let's get ahead and get started. Thank you all for being here. Pleasure to have Gilead management here. There's a lot of topics to go through, including some of the FDA updates today, Andy, and I realized it's very early into the update. But maybe let me turn it over t ...

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies London Healthcare Conference November 15, 2023 4:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Michael Yee - Biotech Analyst, Jeffries Michael Yee Okay, good morning. Thank you everyone for joining us on a morning session here on day two of the Jeffries Global London Healthcare Conference. I'm Mike Yee, one of the biotech analysts at Jeffries, and I'm really pleased to have with us up here on the stage the ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Geoff Meacham - Bank of America Michael Yee - Jefferies Daina Graybosch - Leerink Partners ...

Q323 Financial Results November 7, 2023 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its anticipated full ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jur ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_4480560867daa7897cdca7c4f81be1aa.html ...